Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.

In the prospectively defined protocol-specified analyses of the study, CSFQ changes from baseline indicated improvement in sexual functioning in all treatment groups, although differences versus placebo did not reach statistical significance ( Mathews et al. , 2015 ).

also in 111,027 other papers